West Nile Virus

West Nile Virus clinical study initiated

Published in Drug Week, October 1st, 2004

Avi BioPharma, Inc., (AVII) announced that it will initiate a clinical trial with its Neugene antisense drug candidate, Avi-4020, for the treatment of patients with acute West Nile virus disease who have serious neurological impairment (WNV neuroinvasive disease).

A number of clinical sites located in Arizona and Southern California are expected to participate in this study with the possibility of increasing the number of sites elsewhere based upon disease outbreaks.

"This clinical trial has been designed to provide an additional demonstration of Avi-4020's safety and an opportunity to evaluate potential efficacy of our Neugene antisense drug against...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-10-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry